(Q34343403)

1 August 2017

A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease (English)

1 reference

1 August 2017

0 references

0 references

cognitive dysfunction

1 reference

Pingping He

1

1 reference

1 August 2017

Xinping Ouyang

2

1 reference

1 August 2017

Shouhong Zhou

3

1 reference

1 August 2017

Weidong Yin

4

1 reference

1 August 2017

Chaoke Tang

5

1 reference

1 August 2017

Moshe Laudon

6

1 reference

1 August 2017

Shaowen Tian

7

1 reference

1 August 2017

4 May 2013

1 reference

1 August 2017

Hormones and Behaviour

1 reference

1 August 2017

64

1 reference

1 August 2017

1

1 reference

1 August 2017

1-7

1 reference

Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

When is the hippocampus involved in recognition memory?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Spatial memory, recognition memory, and the hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Functional MT1 and MT2 melatonin receptors in mammals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Alzheimer disease models and human neuropathology: similarities and differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Global prevalence of dementia: a Delphi consensus study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

The modulation of neuronal activity by melatonin: in vitro studies on mouse hippocampal slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Impairment of object recognition memory by rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide(1-42) and fed a high-cholesterol diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Oxidative stress hypothesis in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Relevance of abeta1-42 intrahippocampal injection as an animal model of inflamed Alzheimer's disease brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Melatonin receptors in rat hippocampus: molecular and functional investigations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Inhibition of Alzheimer beta-fibrillogenesis by melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Cardiovascular effects of melatonin receptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Melatonin supplementation delays the decline of adult hippocampal neurogenesis during normal aging of mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

The hormonal Zeitgeber melatonin: role as a circadian modulator in memory processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Melatonin inhibits hippocampal long-term potentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

The worldwide societal costs of dementia: Estimates for 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2013.04.009

10.1016/J.YHBEH.2013.04.009

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference